Oncologists Cheer Melanoma Data

Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people's lives and forming the same conclusion. Instead, as reports leaked out on social media about the findings of the melanoma shot days before the carefully scripted presentation planned for thousands of oncologists gathered in Madrid for the European Society for Medical Oncology meeting  realities diverged.  Madison Muller, Bloomberg News Healthcare Reporter, reports.